Medpace Holdings Inc. (MEDP) saw its stock price plummet 6.15% in after-hours trading on Monday, despite reporting first-quarter earnings that beat analyst expectations. The sharp decline comes as investors appear to be focusing on the company's full-year guidance, which fell short of market estimates.
For the first quarter of 2025, Medpace reported impressive results: - Revenue of $558.57 million, surpassing the IBES estimate of $527.2 million - Earnings per share (EPS) of $3.67, significantly higher than the IBES estimate of $3.06 - Net income of $114.595 million, up from $102.591 million in the same quarter last year
However, the company's outlook for the full year 2025 seems to have disappointed investors: - EPS guidance of $12.26 to $13.04 - Revenue forecast of $2.140 billion to $2.240 billion, representing growth of only 1.5% to 6.2% over 2024 revenue The modest growth projection, coupled with a decrease in net new business awards (down 18.8% to $500.0 million) and a lower book-to-bill ratio of 0.90x, likely contributed to the negative after-hours reaction. These factors suggest potential challenges in maintaining the company's growth trajectory, despite the strong quarterly performance.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.